Adenocarcinoma News and Research

RSS

Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.

Landmark study at Homerton University Hospital confirms GastroPanel®’s diagnostic accuracy

GastroPanel's clinical validation highlights its role in early gastric cancer risk assessment, offering a cost-effective alternative to invasive procedures.

From BIOHIT HealthCare Ltd 26 Feb 2025

High GATA6 expression predicts improved outcomes in pancreatic cancer

This new review article highlights the crucial role of GATA6, a transcription factor, in pancreatic ductal adenocarcinoma (PDA). The article explores GATA6's dual role in cancer progression and its potential as a biomarker and treatment target.

24 Feb 2025

Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for adults with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy, irrespective of PD-L1 expression level or tumor histology.

14 Feb 2025

PAC-MANN blood test could help detect pancreatic cancer at early stages

A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the deadliest cancers.

12 Feb 2025

New immune map uncovers key pancreatic cancer insights

Researchers determine a complex immune infiltrate pattern based on a newly constructed immune map developed using pancreatic cancer cells.

12 Feb 2025

Gut microbes influence how well cancer patients respond to immunotherapy

Researchers discovered that gut microbiota-derived hexa-acylated LPS enhances the effectiveness of anti-PD-1 cancer immunotherapy, while penta-acylated LPS may suppress immune responses.

11 Feb 2025

Insilico Medicine develops highly selective FGFR2/3 dual inhibitor for cancer treatment

Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma.

7 Feb 2025

Pancreatic cancer immune landscape reveals opportunities for personalized therapies

Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to macrophage-based therapies.

7 Feb 2025

Mayo Clinic develops AI tool to visualize complex biological data

Mayo Clinic researchers have pioneered an artificial intelligence (AI) tool, called OmicsFootPrint, that helps convert vast amounts of complex biological data into two-dimensional circular images.

6 Feb 2025

New procedure standard/practice guideline released for fibroblast activation protein PET

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have issued a new procedure standard/practice guideline for the use of fibroblast activation protein (FAP) PET.

25 Jan 2025

Pancreatic cancer insights: How pORG classifications predict survival and guide treatment

Researchers identify distinct molecular and immune profiles that impact the prognosis of patients with metastatic pancreatic ductal adenocarcinoma.

15 Jan 2025

Ultrasensitive ctDNA detection improves risk prediction in early-stage lung cancer

Ultrasensitive ctDNA detection with NeXT Personal shows 81% sensitivity in early-stage lung adenocarcinoma, improving prognostic accuracy and therapy guidance.

15 Jan 2025

New test could predict lung cancer outcomes using tumor DNA

Scientists from the Francis Crick Institute, UCL, UCLH and Personalis have found that a test to detect circulating tumor DNA can predict lung cancer outcome in a Cancer Research UK-funded study.

13 Jan 2025

Short-chain fatty acids propionate and butyrate directly modify chromatin to regulate gene expression

Short-chain fatty acids influence gene regulation and chromatin accessibility, highlighting their role in colorectal cancer and normal cellular processes.

13 Jan 2025

New test predicts lung cancer survival better than current standards

Researchers at the Francis Crick Institute, the UCL Cancer Institute and UCLH have shown that a test called ORACLE can predict lung cancer survival at the point of diagnosis better than currently used clinical risk factors.

9 Jan 2025

Patient-centered reports help reduce worry and improve understanding of test results

In April 2021, a provision in the 21st Century Cures act took effect which required that all medical test results be released to a patient's electronic medical record as soon as they become available.

3 Jan 2025

Genetic mutation in esophageal cancer found to have dual effects

A genetic fault long believed to drive the development of esophageal cancer may in fact play a protective role early in the disease, according to new research published in Nature Cancer.

3 Jan 2025

New nanoparticle platform delivers drug pairs to specific cancer types

Researchers at Tel Aviv University have developed a new platform using polymeric nanoparticles to deliver drug pairs to specific cancer types, including skin cancer and breast cancer.

23 Dec 2024

DTI detects precancerous lesions in the pancreas

Precursor lesions of pancreatic cancer are very difficult to characterize with magnetic resonance imaging (MRI). But now, in a new study, researchers led by Noam Shemesh and Carlos Bilreiro – respectively head of the Preclinical MRI lab at Champalimaud Research and a doctor at the Champalimaud Clinical Centre's Radiology Department – have shown, for the first time, that a particular form of MRI, called Diffusion Tensor Imaging (DTI), is capable of robustly detecting pre-malignant lesions in the pancreas.

13 Dec 2024

Deep learning transforms PDAC diagnosis and treatment

Researchers have successfully developed a deep learning model that classifies pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, into molecular subtypes using histopathology images.